We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
363 hedge funds and large institutions have $10B invested in Royalty Pharma in 2023 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 147 increasing their positions, 110 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
172% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 29
46% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $17.5M
34% more repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 110
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
23% more capital invested
Capital invested by funds: $8.17B → $10B (+$1.88B)
16% more funds holding
Funds holding: 313 → 363 (+50)
13.28% more ownership
Funds ownership: 66.76% → 80.04% (+13%)
Holders
363
Holders Change
+50
Holders Change %
+15.97%
% of All Funds
5.29%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
79
Increased
147
Reduced
110
Closed
29
Calls
$25.5M
Puts
$17.5M
Net Calls
+$8.05M
Net Calls Change
-$20.6M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.22B |
| 2 |
Man Group
London,
United Kingdom
|
+$70.9M |
| 3 |
Amundi
Paris,
France
|
+$57.2M |
| 4 |
Swedbank
Stockholm,
Sweden
|
+$41.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$35M |
Top Sellers
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$67.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$62.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39.6M |
| 4 |
Goldman Sachs
New York
|
-$36.8M |
| 5 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$29.6M |
